Office Action.) Applicants respectfully disagree.

Independent Claims 1, 30, 56, and 57 of Group I require the presence of a polymer

having a "first subunit comprising a first nucleic acid, wherein said first subunit is incorporated

into said polymer using a first subunit precursor comprising said first nucleic acid and an

ethylene-containing moiety." The product disclosed in U.S. Patent No. 5,932,711 ("Boles") is

not incorporated into a polymer. Boles, on the other hand, discloses a polymerizable complex of

an ethylene-containing monomer unit covalently linked to a nucleic acid molecule. As stated in

lines 44-45 of column 4 of Boles, the "polymerized layer acts as a solid matrix which anchors

the nucleic acid molecules to a defined locus. . . . " As illustrated in the Examples of column 14,

the product of *Boles* is embedded into a matrix, such as an acrylamide matrix.

The Examiner is further requested to reconsider the requirement for restriction because a

single inventive concept runs through all of the claims of Groups I and II. This single inventive

concept is the polymer of Group I useful in the treatment of medical conditions. The Examiner

will undoubtedly have to consult with the art directed to the claimed product in the rendering of

any opinion on the patentability of the method claims. Applicants, therefore, respectfully request

the Examiner to reconsider the restriction requirement especially in view of the Official Gazette

Notice of March 26, 1996, which establishes guidelines for the proper treatment of product and

method claims in light of In re Ochiai, 37 U.S.P.Q. 2d 1127 (Fed. Cir. 1995) and In re Brower,

37 U.S.P.Q. 2d 1663 (Fed. Cir. 1996).

Dated: May 7, 2003

Respectfully submitted,

/John Wilson Jones/ Registration No. 31,380

LOCKE LIDDELL & SAPP LLP

600 Travis, Suite 3400

Houston, Texas 77002-3095

Telephone No.: (713) 226-1142

Facsimile No.: (713) 229-2570

2

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify this correspondence is being deposited on this 7th day of May, 2003, under 37 CFR 1.8, with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: May 7, 2003

ana Walraven

22904
PATENT TRADEMARK OFFICE